Agilent Technologies and Ambry Genetics have signed an agreement under which Ambry will use Agilent's SureSelect Target Enrichment System for exome sequencing services, the companies said last week.

Ardy Arianpour, vice president of business development at Ambry, said in a statement that the company is using SureSelect to offer whole-exome capture services for "cancer markers, drug response, and Mendelian disease gene discovery."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
12
Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.